ArticleJournal of diabetes research2026
Identifying Provider Prescribing Practices for GLP-1RAs and SGLT-2is in Patients With Type 2 Diabetes to Address Pharmacoinequity.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characterizing Social Determinants of Health in Patients With Type 2 Diabetes and Liver Disease: Cross-Sectional Survey Study.JMIR formative research · 2026Article
- Identifying Provider Prescribing Practices for GLP-1RAs and SGLT-2is in Patients With Type 2 Diabetes to Address Pharmacoinequity.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Background and Aims: Evidence-based treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with Type 2 diabetes (T2DM) focuses on glycemic control and lifestyle modification to achieve weight loss, which slows the progression of liver disease and reduces the risk of liver-related complications. We aimed to qualitatively explore provider-level determinants in glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium/glucose cotransporter 2 inhibitors (SGLT-2is) prescription. Methods: We identified a cohort of 189 outpatient adult primary care providers who cared for at least 50 annual T2DM patients in a tertiary academic health system in the United States in 2021. GLP-1RA and SGLT-2i prescribing rates were calculated with a median rate of 0.494 (IQR 0.393-0.594). Guided by the Consolidate Framework for Implementation Research, we conducted 1:1 interviews with high-prescribing and low-prescribing providers. All providers interviewed were either MDs or DOs. Results: Nine providers from the high-prescribing quartile (prescribing rate 59.5%-78.6%) and eight from the low-prescribing quartile (prescribing rate 4.8%-39.3%) were interviewed. High-prescribing providers reported more patient-facing hours and exposure to GLP-1RAs and SGLT-2is in residency. All providers cited task-sharing, patient-provider relationship longevity, and medication effectiveness as facilitators of GLP-1RA and SGLT-2i prescription. Barriers to prescribing included medication costs, prior authorization processes, and prescription inertia. Using the Expert Recommendations for Implementing Change, we mapped barriers and facilitators to implementation strategies. Conclusions: This interview series identified key barriers and facilitators of GLP-1RA and SGTL-2i prescription. Implementation strategies may help improve prescribing highly effective, newer treatments in patients with T2DM, including those with metabolic comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.